{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:17:21Z","timestamp":1787163441008,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.14310\/horm.2002.1225","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T08:38:15Z","timestamp":1390984695000},"page":"83-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Medical treatment of hypercalcaemia"],"prefix":"10.1007","volume":"8","author":[{"given":"Polyzois","family":"Makras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,1]]},"reference":[{"key":"8020083_CR1","first-page":"176","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"E Shane","year":"2006","unstructured":"Shane E, Irani D 2006 Hypercalcaemia: Pathogenesis, Clinical Manifestations, Differential Diagnosis and Management. In: Favus MJ, (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society for Bone and Mineral Research, USA; pp, 176\u2013180."},{"key":"8020083_CR2","unstructured":"Parathyroid Hormone-Related Protein: Normal Physiology and its Role in Cancer. Halloran BP, Nissenson BA, (eds) 1992 Parathyroid Hormone-Related Protein: Normal Physiology and its Role in Cancer. USA: CRC Press, Boca Raton, FL."},{"key":"8020083_CR3","first-page":"827","volume-title":"Principles of Bone Biology","author":"GR Mundy","year":"2008","unstructured":"Mundy GR 2008 Role of cytokines, parathyroid hormone and growth factors in malignancy. In: Bilezikian JP, Raisz LG, Rodan GA, (eds). Principles of Bone Biology, Academic Press, New York, NY, USA; pp, 827\u2013836."},{"key":"8020083_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1056\/NEJMcp042806","volume":"352","author":"AF Stewart","year":"2005","unstructured":"Stewart AF, 2005 Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352: 373\u2013379.","journal-title":"N Engl J Med"},{"key":"8020083_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD, 2004 Mechanisms of bone metastasis. N Engl J Med 350: 1655\u20131664.","journal-title":"N Engl J Med"},{"key":"8020083_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-112-7-499","volume":"112","author":"SH Ralston","year":"1990","unstructured":"Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT, 1990 Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 112: 499\u2013504.","journal-title":"Ann Intern Med"},{"key":"8020083_CR7","first-page":"195","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"MJ Horwitz","year":"2006","unstructured":"Horwitz MJ, Stewart AF 2006 Hypercalcemia associated with malignancy. In: Favus MJ, (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society for Bone and Mineral Research, USA; pp, 195\u2013199."},{"key":"8020083_CR8","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, et al, 2003 The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483\u20132494.","journal-title":"N Engl J Med"},{"key":"8020083_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000151222","volume":"89","author":"R Srirajaskanthan","year":"2008","unstructured":"Srirajaskanthan R, McStay M, Toumpanakis C, Meyer T, Caplin ME, 2008 Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review. Neuroendocrinology 89: 48\u201355.","journal-title":"Neuroendocrinology"},{"key":"8020083_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/1097-0142(19910801)68:3<642::AID-CNCR2820680334>3.0.CO;2-A","volume":"68","author":"K Hoekman","year":"1991","unstructured":"Hoekman K, Tjandra YI, Papapoulos SE, 1991 The role of 1, 25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein. Cancer 68: 642\u2013647.","journal-title":"Cancer"},{"key":"8020083_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2265.1994.tb02538.x","volume":"41","author":"DH Schweitzer","year":"1994","unstructured":"Schweitzer DH, Hamdy NA, Frolich M, Zwinderman AH, Papapoulos SE, 1994 Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome. Clin Endocrinol (Oxf) 41: 251\u2013256.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"8020083_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.7326\/0003-4819-121-9-199411010-00001","volume":"121","author":"JF Seymour","year":"1994","unstructured":"Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F, 1994 Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med 121: 633\u2013640.","journal-title":"Ann Intern Med"},{"key":"8020083_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0002-9440(10)63343-3","volume":"165","author":"KN Evans","year":"2004","unstructured":"Evans KN, Taylor H, Zehnder D, et al, 2004 Increased expression of 25-hydroxyvitamin D-1alpha-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol 165: 807\u2013813.","journal-title":"Am J Pathol"},{"key":"8020083_CR14","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/1097-0142(19870501)59:9<1543::AID-CNCR2820590902>3.0.CO;2-L","volume":"59","author":"AH Mudde","year":"1987","unstructured":"Mudde AH, van den Berg H, Boshuis PG, et al, 1987 Ectopic production of 1, 25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer 59: 1543\u20131546.","journal-title":"Cancer"},{"key":"8020083_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4158\/EP.10.2.125","volume":"10","author":"W Eid","year":"2004","unstructured":"Eid W, Wheeler TM, Sharma MD, 2004 Recurrent hypercalcemia due to ectopic production of parathyroid hormone-related protein and intact parathyroid hormone in a single patient with multiple malignancies. Endocr Pract 10: 125\u2013128.","journal-title":"Endocr Pract"},{"key":"8020083_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4158\/EP.12.3.302","volume":"12","author":"EJ Mahoney","year":"2006","unstructured":"Mahoney EJ, Monchik JM, Donatini G, De Lellis R, 2006 Life-threatening hypercalcemia from a hepatocellular carcinoma secreting intact parathyroid hormone: localization by sestamibi single-photon emission computed tomographic imaging. Endocr Pract 12: 302\u2013306.","journal-title":"Endocr Pract"},{"key":"8020083_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","volume":"149","author":"SB LeGrand","year":"2008","unstructured":"LeGrand SB, Leskuski D, Zama I, 2008 Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 149: 259\u2013263.","journal-title":"Ann Intern Med"},{"key":"8020083_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1385\/BMM:1:1:65","volume":"1","author":"NA Hamdy","year":"2002","unstructured":"Hamdy NA, Papapoulos SE, 2002 Management of malignancy-associated hypercalcaemia. Clinical Reviews in Bone and Mineral Metabolism 1: 65\u201376.","journal-title":"Clinical Reviews in Bone and Mineral Metabolism"},{"key":"8020083_CR19","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","volume":"22","author":"SE Papapoulos","year":"2008","unstructured":"Papapoulos SE, 2008 Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 22: 831\u2013847.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"8020083_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.4065\/81.8.1047","volume":"81","author":"MQ Lacy","year":"2006","unstructured":"Lacy MQ, Dispenzieri A, Gertz MA, et al, 2006 Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81: 1047\u20131053.","journal-title":"Mayo Clin Proc"},{"key":"8020083_CR21","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00520-003-0477-1","volume":"11","author":"M Pecherstorfer","year":"2003","unstructured":"Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M, Bergstrom B, 2003 Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 11: 539\u2013547.","journal-title":"Support Care Cancer"},{"key":"8020083_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/sj.bjc.6600249","volume":"86","author":"S Shah","year":"2002","unstructured":"Shah S, Hardy J, Rees E, et al, 2002 Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? Br J Cancer 86: 1235\u20131237.","journal-title":"Br J Cancer"},{"key":"8020083_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/172460080702200104","volume":"22","author":"A Veri","year":"2007","unstructured":"Veri A, D\u2019Andrea MR, Bonginelli P, Gasparini G, 2007 Clinical usefulness of bisphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers. Int J Biol Markers 22: 24\u201333.","journal-title":"Int J Biol Markers"},{"key":"8020083_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J, et al, 2001 Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558\u2013567.","journal-title":"J Clin Oncol"},{"key":"8020083_CR25","first-page":"69","volume":"1","author":"SE Papapoulos","year":"1986","unstructured":"Papapoulos SE, Harinck HI, Bijvoet OL, Gleed JH, Fraher LJ, O\u2019Riordan JL, 1986 Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD. Bone Miner 1: 69\u201378.","journal-title":"Bone Miner"},{"key":"8020083_CR26","first-page":"200","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"JS Adams","year":"2006","unstructured":"Adams JS, Hewison M 2006 Hypercalcemia caused by granuloma-forming disorders. In: Favus MJ, (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society for Bone and Mineral Research, USA; pp, 200\u2013202."},{"key":"8020083_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.7326\/0003-4819-111-5-437","volume":"111","author":"JS Adams","year":"1989","unstructured":"Adams JS, Diz MM, Sharma OP, 1989 Effective reduction in the serum 1, 25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 111: 437\u2013438.","journal-title":"Ann Intern Med"},{"key":"8020083_CR28","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1210\/jcem-70-4-1090","volume":"70","author":"JS Adams","year":"1990","unstructured":"Adams JS, Sharma OP, Diz MM, Endres DB, 1990 Ketoconazole decreases the serum 1, 25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab 70: 1090\u20131095.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR29","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-07-5234","volume":"14","author":"A Lipton","year":"2008","unstructured":"Lipton A, Steger GG, Figueroa J, et al, 2008 Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 14: 6690\u20136696.","journal-title":"Clin Cancer Res"},{"key":"8020083_CR30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","volume":"16","author":"PJ Bekker","year":"2001","unstructured":"Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR, 2001 The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16: 348\u2013360.","journal-title":"J Bone Miner Res"},{"key":"8020083_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00774-005-0640-5","volume":"24","author":"H Iguchi","year":"2006","unstructured":"Iguchi H, Aramaki Y, Maruta S, Takiguchi S, 2006 Effects of anti-parathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice. J Bone Miner Metab 24: 16\u201319.","journal-title":"J Bone Miner Metab"},{"key":"8020083_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1053\/j.seminoncol.2003.08.019","volume":"30","author":"K Sato","year":"2003","unstructured":"Sato K, Onuma E, Yocum RC, Ogata E, 2003 Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin Oncol 30: 167\u2013173.","journal-title":"Semin Oncol"},{"key":"8020083_CR33","first-page":"181","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"JP Bilezikian","year":"2006","unstructured":"Bilezikian JP, Silverberg SJ 2006 Primary Hyperparathyroidism. In: Favus MJ, (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society for Bone and Mineral Research, USA; pp, 181\u2013185."},{"key":"8020083_CR34","volume-title":"Normocalcemic Primary Hyperparathyroidism: Update on a New Clinical Phenotype","author":"H Lowe","year":"2008","unstructured":"Lowe H, McMahon D, Walker M, Rubin M, Bilezikian J, Silverberg S, 2008 Normocalcemic Primary Hyperparathyroidism: Update on a New Clinical Phenotype. 30th American Society for Bone and Mineral Research Annual Meeting, 12\u201316 September, Montreal, Canada."},{"key":"8020083_CR35","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1210\/jc.2002-021370","volume":"87","author":"JP Bilezikian","year":"2002","unstructured":"Bilezikian JP, Potts JT Jr., Fuleihan G, et al, 2002 Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 87: 5353\u20135361.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1210\/jc.2008-1763","volume":"94","author":"JP Bilezikian","year":"2009","unstructured":"Bilezikian JP, Khan AA, Potts JT Jr, Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism, 2009 Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94: 335\u2013339.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0025-6196(11)61031-8","volume":"82","author":"B Farford","year":"2007","unstructured":"Farford B, Presutti RJ, Moraghan TJ, 2007 Nonsurgical management of primary hyperparathyroidism. Mayo Clin Proc 82: 351\u2013355.","journal-title":"Mayo Clin Proc"},{"issue":"Suppl1","key":"8020083_CR38","first-page":"S69","volume":"8","author":"NA Hamdy","year":"1987","unstructured":"Hamdy NA, Gray RE, McCloskey E, et al, 1987 Clodronate in the medical management of hyperparathyroidism. Bone 8: Suppl 1: S69\u2013S77.","journal-title":"Bone"},{"key":"8020083_CR39","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","volume":"16","author":"M Rossini","year":"2001","unstructured":"Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S, 2001 Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 16: 113\u2013119.","journal-title":"J Bone Miner Res"},{"key":"8020083_CR40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/jc.2002-020890","volume":"88","author":"CC Chow","year":"2003","unstructured":"Chow CC, Chan WB, Li JK, et al, 2003 Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88: 581\u2013587.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR41","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1210\/jc.2001-010385","volume":"87","author":"CR Parker","year":"2002","unstructured":"Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ, 2002 Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab 87: 4482\u20134489.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR42","first-page":"19","volume":"25","author":"P Makras","year":"2005","unstructured":"Makras P, Kaltsas GA, Athanasoulis T, et al, 2005 Treatment with oral bisphosphonates can increase the sensitivity of sestamibi radionuclide imaging in patients with primary hyperparathyroidism. Int J Clin Pharmacol Res 25: 19\u201328.","journal-title":"Int J Clin Pharmacol Res"},{"key":"8020083_CR43","first-page":"230","volume":"108","author":"SL Greenspan","year":"1996","unstructured":"Greenspan SL, Holland S, Maitland-Ramsey L, et al, 1996 Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Physicians 108: 230\u2013238.","journal-title":"Proc Assoc Am Physicians"},{"key":"8020083_CR44","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1210\/jc.2003-030908","volume":"89","author":"AA Khan","year":"2004","unstructured":"Khan AA, Bilezikian JP, Kung AW, et al, 2004 Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89: 3319\u20133325.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR45","first-page":"1067","volume":"77","author":"CA Reasner","year":"1993","unstructured":"Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR, 1993 Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 77: 1067\u20131071.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR46","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1001\/archsurg.141.7.696","volume":"141","author":"JI Lew","year":"2006","unstructured":"Lew JI, Solorzano CC, Irvin GL III, 2006 Long-term results of parathyroidectomy for hypercalcemic crisis. Arch Surg 141: 696\u2013699.","journal-title":"Arch Surg"},{"key":"8020083_CR47","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jc.2002-020667","volume":"88","author":"MR Rubin","year":"2003","unstructured":"Rubin MR, Lee KH, McMahon DJ, Silverberg SJ, 2003 Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88: 1174\u20131178.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR48","first-page":"76","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"MJ Favus","year":"2006","unstructured":"Favus MJ, Bushinsky D, Lemann JJ 2006 Regulation of calcium, magnesium, and phosphate metabolism. In: Favus MJ, (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society for Bone and Mineral Research, USA; pp, 76\u201383."},{"key":"8020083_CR49","doi-asserted-by":"publisher","first-page":"5644","DOI":"10.1210\/jc.2002-021597","volume":"88","author":"DM Shoback","year":"2003","unstructured":"Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M, 2003 The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 88: 5644\u20135649.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR50","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth EF, Heaton WH, Miller M, et al, 2004 Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 308: 627\u2013635.","journal-title":"J Pharmacol Exp Ther"},{"key":"8020083_CR51","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham J, Danese M, Olson K, Klassen P, Chertow GM, 2005 Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793\u20131800.","journal-title":"Kidney Int"},{"key":"8020083_CR52","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","volume":"67","author":"SM Moe","year":"2005","unstructured":"Moe SM, Chertow GM, Coburn JW, et al, 2005 Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67: 760\u2013771.","journal-title":"Kidney Int"},{"key":"8020083_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/jc.2004-0842","volume":"90","author":"M Peacock","year":"2005","unstructured":"Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D, 2005 Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90: 135\u2013141.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl","key":"8020083_CR54","first-page":"17","volume":"18","author":"M Peacock","year":"2003","unstructured":"Peacock M, Scumpia S, Bolognese MA, et al, 2003 Long-term control of primary hyperparathyroidism with cinacalcet HL (AMG 073). J Bone Miner Res 18: Suppl: 17.","journal-title":"J Bone Miner Res"},{"key":"8020083_CR55","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1210\/jc.2007-0585","volume":"92","author":"SJ Silverberg","year":"2007","unstructured":"Silverberg SJ, Rubin MR, Faiman C, et al, 2007 Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 92: 3803\u20133808.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020083_CR56","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1365-2265.2008.03301.x","volume":"69","author":"A Faggiano","year":"2008","unstructured":"Faggiano A, Tavares LB, Tauchmanova L, et al, 2008 Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients. Clin Endocrinol (Oxf) 69: 756\u2013762.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"8020083_CR57","first-page":"188","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"SJ Marx","year":"2006","unstructured":"Marx SJ 2006 Familial hypocalciuric hypercalcemia. In: Favus MJ, (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society for Bone and Mineral Research, USA; pp, 188\u2013190."},{"key":"8020083_CR58","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1152\/physrev.2001.81.1.239","volume":"81","author":"EM Brown","year":"2001","unstructured":"Brown EM, MacLeod RJ, 2001 Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239\u2013297.","journal-title":"Physiol Rev"},{"key":"8020083_CR59","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.berh.2007.11.006","volume":"22","author":"OI Egbuna","year":"2008","unstructured":"Egbuna OI, Brown EM, 2008 Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract Res Clin Rheumatol 22: 129\u2013148.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"8020083_CR60","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1365-2265.2007.03027.x","volume":"68","author":"B Festen-Spanjer","year":"2008","unstructured":"Festen-Spanjer B, Haring CM, Koster JB, Mudde AH, 2008 Correction of hypercalcaemia by cinacalcet in familial hypocalciuric hypercalcaemia. Clin Endocrinol (Oxf) 68: 324\u2013325.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"8020083_CR61","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2796.2006.01684.x","volume":"260","author":"HJ Timmers","year":"2006","unstructured":"Timmers HJ, Karperien M, Hamdy NA, de Boer H, Hermus AR, 2006 Normalization of serum calcium by cinacalcet in a patient with hypercalcaemia due to a de novo inactivating mutation of the calcium-sensing receptor. J Intern Med 260: 177\u2013182.","journal-title":"J Intern Med"},{"key":"8020083_CR62","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(79)91076-6","volume":"1","author":"SE Papapoulos","year":"1979","unstructured":"Papapoulos SE, Clemens TL, Fraher LJ, Lewin IG, Sandler LM, O\u2019Riordan JL, 1979 1, 25-dihydroxychole-calciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. Lancet 1: 627\u2013630.","journal-title":"Lancet"},{"issue":"MJ","key":"8020083_CR63","first-page":"203","volume":"Favus","author":"JJ Wysolmerski","year":"2006","unstructured":"Wysolmerski JJ 2006 Miscellaneous causes of hypercalcemia. In: Favus MJ, (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society for Bone and Mineral Research, USA; pp, 203\u2013208.","journal-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism"},{"key":"8020083_CR64","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF, 2007 Vitamin D deficiency. N Engl J Med 357: 266\u201381.","journal-title":"N Engl J Med"},{"key":"8020083_CR65","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/9780470623992.ch71","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"P Lips","year":"2008","unstructured":"Lips P, van Schoor NM, Bravenboer N 2008 Vitamin D-related Disorders. In: Rosen CJ, (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, American Society for Bone and Mineral Research, USA; pp, 329\u2013335."}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1225\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T10:34:15Z","timestamp":1739097255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["8020083"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1225","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"22 January 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}